Arbutus Biopharma Corp expected to post a loss of 9 cents a share - Earnings Preview

Arbutus Biopharma

04/11/2024 15:45

* Arbutus Biopharma Corp  ABUS.OQ   ABUS.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 6
for the period ending January 1 0001
    * The Warminster Pennsylvania-based  company is expected to
report
a 60.1% decrease in revenue to $1.86 million from $4.66 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Arbutus Biopharma Corp
is for
a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arbutus
Biopharma
Corp is $5.00​, above​ its last closing price of $3.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.09       -0.10      -0.11     Missed  -13.6
 Mar. 31 2024  -0.11       -0.11      -0.10     Beat    9.1
 Dec. 31 2023  -0.12       -0.12      -0.12     Met     -1.7​
 Sep. 30 2023  -0.11       -0.11      -0.12     Missed  -5.4
 ​​Jun.        -0.11       -0.11      -0.10     Beat    10.9
 30 2023                                                
 Mar. 31 2023  -0.14       -0.14      -0.10     Beat    26.5​
 Dec. 31 2022  -0.13       -0.13      -0.14     Missed  -5.2
 Sep. 30 2022  -0.13       -0.13      -0.12     Beat    6.3
 This summary was machine generated November 4 at 15:45 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)